uploads///Chart  Orencia

Bristol-Myers Squibb’s Immunoscience Products

Mike Benson - Author
By

Sep. 29 2017, Updated 9:11 a.m. ET

Immunoscience products

Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.

The above chart shows revenues from Orencia over the last few quarters.

Article continues below advertisement

Orencia

Orencia is a drug that reduces the pain in moderate-to-severe rheumatoid arthritis and also helps to reduce further joint damage. Orencia reported 10% growth in revenues to $650 million in 2Q17, compared to revenues of $593 million in 2Q16. The growth in revenues was driven by an increase in sales in US as well as international markets.

Orencia reported 12% growth in US sales to $449 million in 2Q17, compared to revenues of $401 million in 2Q16.

Other brands from Bristol-Myers Squibb

The other brands from Bristol-Myers Squibb’s product portfolio include various products that have lost exclusivity in major markets, over-the-counter products, and royalty revenues. Overall, the revenues from other brands fell ~16% to $479 million in 2Q17, compared to $572 million for 2Q16.

Other brands reported a 5% fall in US sales to $92 million in 2Q17, compared to $97 million in 2Q16.

To divest company-specific risks, investors can consider ETFs like the First Trust NASDAQ Pharmaceuticals (FTXH), which invests 4.6% of its portfolio in Bristol-Myers Squibb (BMY). FTXH also invests 8.2% in Pfizer (PFE), 9.1% in Abbott Laboratories (ABT), and 4.1% in Eli Lilly and Co. (LLY).

Advertisement

Latest Bristol-Myers Squibb Co. News and Updates

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.